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Vaccines based on plasmid DNA (pDNA) or recombinant
vesicular stomatitis virus (rVSV) vectors elicit HIV-1-spe-
cific cellular and humoral immune responses in small ani-
mal models. However, hurdles remain with each of these
vaccine modalities before they can be considered for
widespread clinical use. For pDNA vaccines, early clinical
studies indicate that additional measures are needed to
improve immunogenicity. For rVSV-based vaccines, issues
related to the potential neurovirulence of the prototype
vector represent a safety concern.
Adjuvant development and pDNA vector optimization
are two important elements of current DNA vaccine
research. Cytokine expression plasmids may function as
potent adjuvants, and in fact, we have observed that plas-
mid-encoded IL-12 can substantially enhance immune
responses in non-human primates. In addition, it is
hypothesized that broad immune responses against mul-
tiple HIV antigens will be required to protect against infec-
tion and/or disease progression. Results from studies will
be presented in which several pDNA vaccine designs were
tested for their ability to elicit broadly reactive immune
responses to multiple HIV antigens.
To address safety concerns related to use of rVSV vectors in
humans, a range of further attenuated vector candidates
has been developed and screened for neurovirulence in
small animal models and nonhuman primates. Attenu-
ated vectors have been identified that cause minimal CNS
lesions after intracranial inoculation similar to those seen
in control animals. Importantly, a number of these further
attenuated vectors retained levels of immunogenicity in
mice equivalent to prototype rVSV vectors, and have been
advanced into nonhuman primate immunogenicity stud-
ies.
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